HomeINBX • NASDAQ
Inhibrx Biosciences Inc
add
$14.15
3.54%
Pre-market:(0.00%)0.00
$14.15
Closed: Mar 14, 4:09:53 AM UTC-4 · USD · NASDAQ · Disclaimer
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 7.90M | 0.19% |
Net income | -43.86M | 15.30% |
Net profit margin | — | — |
Earnings per share | -2.84 | — |
EBITDA | -46.04M | -1.13% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 196.33M | — |
Total assets | 222.56M | — |
Total liabilities | 44.10M | — |
Total equity | 178.47M | — |
Shares outstanding | 14.48M | — |
Price to book | 1.19 | — |
Return on assets | -48.65% | — |
Return on capital | -58.23% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -43.86M | 15.30% |
Cash from operations | -30.28M | 44.18% |
Cash from investing | -247.00K | 69.54% |
Cash from financing | 0.00 | -100.00% |
Net change in cash | -30.53M | -121.08% |
Free cash flow | -16.31M | — |
Previous close
$14.67
Day range
$14.12 - $15.29
Year range
$10.80 - $35.42
Market cap
204.83M USD
Avg Volume
98.21K
P/E ratio
0.12
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
2024
Headquarters
Website
Employees
173
